Clinical utility of reverse phase protein array for molecular classification of breast cancer

Abstract Reverse Phase Protein Array (RPPA) represents a sensitive and high-throughput technique allowing simultaneous quantitation of protein expression levels in biological samples. This study aimed to confirm the ability of RPPA to classify archival formalin-fixed paraffin-embedded (FFPE) breast cancer tissues into molecular classes used in the Nottingham prognostic index plus (NPI+) determined by immunohistochemistry (IHC). Proteins were extracted from FFPE breast cancer tissues using three extraction protocols: the Q-proteome FFPE Tissue Kit (Qiagen, Hilden, Germany) and two in-house methods using Laemmli buffer with either incubation for 20 min or 2 h at 105 °C. Two preparation methods, full-face sections and macrodissection, were used to assess the yield and quality of protein extracts. Ten biomarkers used for the NPI+ (ER, PgR, HER2, Cytokeratins 5/6 and 7/8, EGFR, HER3, HER4, p53 and Mucin 1) were quantified using RPPA and compared to results determined by IHC. The Q-proteome FFPE Tissue Kit produced significantly higher protein concentration and signal intensities. The intra- and inter-array reproducibility assessment indicated that RPPA using FFPE lysates was a highly reproducible and robust technique. Expression of the biomarkers individually and in combination using RPPA was highly consistent with IHC results. Macrodissection of the invasive tumour component gave more reliable results with the majority of biomarkers determined by IHC, (80 % concordance) compared with full-face sections (60 % concordance). Our results provide evidence for the technical feasibility of RPPA for high-throughput protein expression profiling of FFPE breast cancer tissues. The sensitivity of the technique is related to the quality of extracted protein and purity of tumour tissue. RPPA could provide a quantitative technique alternative to IHC for the biomarkers used in the NPI+.

[1]  Gallya Gannot,et al.  Evaluation of non-formalin tissue fixation for molecular profiling studies. , 2002, The American journal of pathology.

[2]  H. Höfler,et al.  Guided protein extraction from formalin‐fixed tissues for quantitative multiplex analysis avoids detrimental effects of histological stains , 2008, Proteomics. Clinical applications.

[3]  R. Elledge,et al.  Prognostic and predictive value of p53 and p21 in breast cancer , 2004, Breast Cancer Research and Treatment.

[4]  Heiko A. Mannsperger,et al.  RPPanalyzer: Analysis of reverse-phase protein array data , 2010, Bioinform..

[5]  P. Tighe,et al.  A pro-inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptor-associated periodic syndrome (TRAPS) , 2014, European journal of immunology.

[6]  G. Ball,et al.  Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer , 2014, British Journal of Cancer.

[7]  A. Tanca,et al.  Generation of high‐quality protein extracts from formalin‐fixed, paraffin‐embedded tissues , 2009, Proteomics.

[8]  C. Schmidt,et al.  Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification , 2010, Proteome Science.

[9]  Michael Pawlak,et al.  Multiple Protein Analysis of Formalin-fixed and Paraffin-embedded Tissue Samples with Reverse phase Protein Arrays , 2013, Molecular & Cellular Proteomics.

[10]  K. Syrigos,et al.  Analytic Variability in Immunohistochemistry Biomarker Studies , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[11]  C. Schmidt,et al.  Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs , 2012, Oncogenesis.

[12]  Mariaelena Pierobon,et al.  Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. , 2008, Journal of proteome research.

[13]  Stefan Wiemann,et al.  Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer , 2012, Molecular systems biology.

[14]  Stefan Wiemann,et al.  Infrared‐based protein detection arrays for quantitative proteomics , 2007, Proteomics.

[15]  E B Cox,et al.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.

[16]  E. Petricoin,et al.  Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab. , 2014, Journal of proteome research.

[17]  R. Casadonte,et al.  Proteomic analysis of formalin-fixed paraffin-embedded tissue by MALDI imaging mass spectrometry , 2011, Nature Protocols.

[18]  K. Coombes,et al.  A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers , 2010, Clinical Proteomics.

[19]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[20]  T. Veenstra,et al.  Unravelling the proteome of formalin-fixed paraffin-embedded tissue. , 2006, Briefings in functional genomics & proteomics.

[21]  E. Petricoin,et al.  One-Step Preservation of Phosphoproteins and Tissue Morphology at Room Temperature for Diagnostic and Research Specimens , 2011, PloS one.

[22]  J. Nährig,et al.  Quantitative protein analysis from formalin‐fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis , 2007, The Journal of pathology.

[23]  E. Petricoin,et al.  Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. , 2011, The American journal of pathology.

[24]  J. Langridge,et al.  Initial Development and Validation of a Novel Extraction Method for Quantitative Mining of the Formalin-Fixed, Paraffin-Embedded Tissue Proteome for Biomarker Investigations , 2010, Journal of proteome research.

[25]  G. Ball,et al.  Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers , 2013, British Journal of Cancer.

[26]  S. Nishizuka,et al.  Reverse-phase protein lysate microarrays for cell signaling analysis , 2008, Nature Protocols.

[27]  Yiling Lu,et al.  Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. , 2010, Cancer research.

[28]  Yanxiang Cao,et al.  Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. , 2009, Archives of pathology & laboratory medicine.

[29]  K. Becker,et al.  Producing reverse phase protein microarrays from formalin-fixed tissues. , 2011, Methods in molecular biology.

[30]  Emanuel F Petricoin,et al.  Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy. , 2007, Cancer genomics & proteomics.

[31]  I. Ellis,et al.  Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study , 2014, Breast Cancer Research and Treatment.

[32]  D. Barnes,et al.  Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems , 2000, Journal of clinical pathology.